Slate Medicines has raised $130 million in Series A funding to advance anti-PACAP therapies. These therapies are aimed at treating migraines. The company thus secured funds for the further development of its drugs. Anti-PACAP drugs target a specific mechanism associated with migraine. The funding round will support clinical trials and research. Slate Medicines specializes in innovative approaches to neurological diseases. This move will strengthen their position in the field of migraine treatment.